Trefoil factors in inflammatory bowel disease

World Journal of Gastroenterology

Volumn 20, Issue 12, 2014, Pages 3223-3230

  Aamann, Luise ^a   Vestergaard, Else Marie ^a   Grønbæk, Henning ^a  

^a AARHUS UNIVERSITY HOSPITAL   (Denmark)

Author keywords

Crohn's disease; Inflammation; Inflammatory bowel disease; Key words trefoil factors; Ulcerative colitis

Indexed keywords

COMPLEMENTARY DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTESTINAL TREFOIL FACTOR; MESSENGER RNA; MUCIN; TUMOR NECROSIS FACTOR ALPHA; BIOLOGICAL MARKER; PEPTIDE; TFF1 PROTEIN, HUMAN; TFF3 PROTEIN, HUMAN; TREFOIL FACTOR; TUMOR SUPPRESSOR PROTEIN;

ANGIOGENESIS; ARTICLE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CLINICAL TRIAL (TOPIC); CROHN DISEASE; GASTROINTESTINAL TRACT FUNCTION; HUMAN; IMMUNE RESPONSE; INFLAMMATORY BOWEL DISEASE; INTESTINE MUCOSA PERMEABILITY; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REGULATORY MECHANISM; ULCERATIVE COLITIS; ANIMAL; APOPTOSIS; GENE EXPRESSION REGULATION; GENETIC VARIABILITY; GENETICS; IMMUNOLOGY; INFLAMMATION; METABOLISM;

ANIMALS; APOPTOSIS; BIOLOGICAL MARKERS; COLITIS, ULCERATIVE; CROHN DISEASE; GENE EXPRESSION REGULATION; GENETIC VARIATION; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; PEPTIDES; TUMOR SUPPRESSOR PROTEINS;

EID: 84896942421     PISSN: 10079327     EISSN: 22192840     Source Type: Journal    
DOI: 10.3748/wjg.v20.i12.3223     Document Type: Article

References (76)

1. Knights D, Lassen KG, Xavier RJ. Advances in infamma-tory bowel disease pathogenesis: linking host genetics and the microbiome. Gut 2013; 62: 1505-1510 [PMID: 24037875 DOI: 10.1136/gutjnl-2012-303954]
2. Taupin D, Podolsky DK. Trefoil factors: initiators of mu-cosal healing. Nat Rev Mol Cell Biol 2003; 4: 721-732 [PMID: 14506475 DOI: 10.1038/nrm1203]
3. Podolsky DK. Mechanisms of regulatory peptide action in the gastrointestinal tract: trefoil peptides. J Gastroenterol 2000; 35 Suppl 12: 69-74 [PMID: 10779222]
4. Kjellev S. The trefoil factor family - small peptides with multiple functionalities. Cell Mol Life Sci 2009; 66: 1350-1369 [PMID: 19099184 DOI: 10.1007/s00018-008-8646-5]
5. Thim L. A new family of growth factor-like peptides. 'Trefoil' disulphide loop structures as a common feature in breast cancer associated peptide (pS2), pancreatic spasmolytic polypeptide (PSP), and frog skin peptides (spas-molysins). FEBS Lett 1989; 250: 85-90 [PMID: 2737304 DOI: 10.1016/0014-5793(89)80690-8]
6. Thim L, Wöldike HF, Nielsen PF, Christensen M, Lynch-Devaney K, Podolsky DK. Characterization of human and rat intestinal trefoil factor produced in yeast. Biochemistry 1995; 34: 4757-4764 [PMID: 7718582 DOI: 10.1021/ bi00014a033]
7. Jørgensen KH, Thim L, Jacobsen HE. Pancreatic spasmolytic polypeptide (PSP): I. Preparation and initial chemical characterization of a new polypeptide from porcine pancreas. Regul Pept 1982; 3: 207-219 [PMID: 6896240 DOI: 10.1016/0167-0115(82)90126-4]
8. Tomasetto C, Rio MC, Gautier C, Wolf C, Hareuveni M, Chambon P, Lathe R. hSP, the domain-duplicated homolog of pS2 protein, is co-expressed with pS2 in stomach but not in breast carcinoma. EMBO J 1990; 9: 407-414 [PMID: 2303034]
9. Hanby AM, Poulsom R, Singh S, Elia G, Jeffery RE, Wright NA. Spasmolytic polypeptide is a major antral peptide: distribution of the trefoil peptides human spasmolytic poly-peptide and pS2 in the stomach. Gastroenterology 1993; 105: 1110-1116 [PMID: 8405856]
10. Masiakowski P, Breathnach R, Bloch J, Gannon F, Krust A, Chambon P. Cloning of cDNA sequences of hormone-regulated genes from the MCF-7 human breast cancer cell line. Nucleic Acids Res 1982; 10: 7895-7903 [PMID: 6897676 DOI: 10.1093/nar/10.24.7895]
11. Rio MC, Bellocq JP, Daniel JY, Tomasetto C, Lathe R, Che-nard MP, Batzenschlager A, Chambon P. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science 1988; 241: 705-708 [PMID: 3041593 DOI: 10.1126/science.3041593]
12. Suemori S, Lynch-Devaney K, Podolsky DK. Identifcation and characterization of rat intestinal trefoil factor: tissue-and cell-specifc member of the trefoil protein family. Proc Natl Acad Sci USA 1991; 88: 11017-11021 [PMID: 1763017 DOI: 10.1073/pnas.88.24.11017]
13. Hauser F, Poulsom R, Chinery R, Rogers LA, Hanby AM, Wright NA, Hoffmann W. hP1.B, a human P-domain peptide homologous with rat intestinal trefoil factor, is expressed also in the ulcer-associated cell lineage and the uterus. Proc Natl Acad Sci USA 1993; 90: 6961-6965 [PMID: 8346203 DOI: 10.1073/pnas.90.15.6961]
14. Podolsky DK, Lynch-Devaney K, Stow JL, Oates P, Murgue B, DeBeaumont M, Sands BE, Mahida YR. Identifcation of human intestinal trefoil factor. Goblet cell-specifc expres sion of a peptide targeted for apical secretion. J Biol Chem 1993; 268: 6694-6702 [PMID: 8454642]
15. Madsen J, Nielsen O, Tornøe I, Thim L, Holmskov U. Tissue localization of human trefoil factors 1, 2, and 3. J Histochem Cytochem 2007; 55: 505-513 [PMID: 17242463 DOI: 10.1369/ jhc.6A7100.2007]
16. Efstathiou JA, Noda M, Rowan A, Dixon C, Chinery R, Jawhari A, Hattori T, Wright NA, Bodmer WF, Pignatelli M. Intestinal trefoil factor controls the expression of the adeno-matous polyposis coli-catenin and the E-cadherin-catenin complexes in human colon carcinoma cells. Proc Natl Acad Sci USA 1998; 95: 3122-3127 [PMID: 9501226 DOI: 10.1073/ pnas.95.6.3122]
17. Taupin DR, Kinoshita K, Podolsky DK. Intestinal trefoil factor confers colonic epithelial resistance to apoptosis. Proc Natl Acad Sci USA 2000; 97: 799-804 [PMID: 10639160 DOI: 10.1073/pnas.97.2.799]
18. Kinoshita K, Taupin DR, Itoh H, Podolsky DK. Distinct pathways of cell migration and antiapoptotic response to epithelial injury: structure-function analysis of human intestinal trefoil factor. Mol Cell Biol 2000; 20: 4680-4690 [PMID: 10848594 DOI: 10.1128/MCB.20.13.4680-4690.2000]
19. Bossenmeyer-Pourié C, Kannan R, Ribieras S, Wendling C, Stoll I, Thim L, Tomasetto C, Rio MC. The trefoil fac tor 1 participates in gastrointestinal cell differentiation by delaying G1-S phase transition and reducing apoptosis. J Cell Biol 2002; 157: 761-770 [PMID: 12034770 DOI: 10.1083/ jcb200108056]
20. Chen YH, Lu Y, De Plaen IG, Wang LY, Tan XD. Transcription factor NF-kappaB signals antianoikic function of trefoil factor 3 on intestinal epithelial cells. Biochem Biophys Res Commun 2000; 274: 576-582 [PMID: 10924320 DOI: 10.1006/ bbrc.2000.3176]
21. Hermiston ML, Gordon JI. Infammatory bowel disease and adenomas in mice expressing a dominant negative N-cad-herin. Science 1995; 270: 1203-1207 [PMID: 7502046 DOI: 10.1126/science.270.5239.1203]
22. Xu LF, Teng X, Guo J, Sun M. Protective effect of intestinal trefoil factor on injury of intestinal epithelial tight junction induced by platelet activating factor. Infammation 2012; 35: 308-315 [PMID: 21452036 DOI: 10.1007/s10753-011-9320-x]
23. Meyer zum Büschenfelde D, Tauber R, Huber O. TFF3-peptide increases transepithelial resistance in epithelial cells by modulating claudin-1 and -2 expression. Peptides 2006; 27: 3383-3390 [PMID: 17018241]
24. Rodrigues S, Van Aken E, Van Bocxlaer S, Attoub S, Nguyen QD, Bruyneel E, Westley BR, May FE, Thim L, Mareel M, Gespach C, Emami S. Trefoil peptides as proangiogenic factors in vivo and in vitro: implication of cyclooxygenase-2 and EGF receptor signaling. FASEB J 2003; 17: 7-16 [PMID: 12522107 DOI: 10.1096/fj.02-0201com]
25. Podolsky DK. Lessons from genetic models of infamma-tory bowel disease. Acta Gastroenterol Belg 1997; 60: 163-165 [PMID: 9260328]
26. Pullan RD, Thomas GA, Rhodes M, Newcombe RG, Williams GT, Allen A, Rhodes J. Thickness of adherent mucus gel on colonic mucosa in humans and its relevance to colitis. Gut 1994; 35: 353-359 [PMID: 8150346 DOI: 10.1136/gut.35.3.353]
27. Tytgat KM, Opdam FJ, Einerhand AW, Büller HA, Dekker J. MUC2 is the prominent colonic mucin expressed in ul-cerative colitis. Gut 1996; 38: 554-563 [PMID: 8707087 DOI: 10.1136/gut.38.4.554]
28. Kindon H, Pothoulakis C, Thim L, Lynch-Devaney K, Po-dolsky DK. Trefoil peptide protection of intestinal epithelial barrier function: cooperative interaction with mucin glyco-protein. Gastroenterology 1995; 109: 516-523 [PMID: 7615201 DOI: 10.1016/0016-5085(95)90340-2]
29. Longman RJ, Douthwaite J, Sylvester PA, Poulsom R, Cor-field AP, Thomas MG, Wright NA. Coordinated localisation of mucins and trefoil peptides in the ulcer associated cell lineage and the gastrointestinal mucosa. Gut 2000; 47: 792-800 [PMID: 11076877 DOI: 10.1136/gut.47.6.792]
30. Tanaka S, Podolsky DK, Engel E, Guth PH, Kaunitz JD. Human spasmolytic polypeptide decreases proton permeation through gastric mucus in vivo and in vitro. Am J Physiol 1997; 272: G1473-G1480 [PMID: 9227484]
31. Thim L, Madsen F, Poulsen SS. Effect of trefoil factors on the viscoelastic properties of mucus gels. Eur J Clin Invest 2002; 32: 519-527 [PMID: 12153553 DOI: 10.1046/j.1365-2362.2002.01014. x]
32. Tomasetto C, Masson R, Linares JL, Wendling C, Lefebvre O, Chenard MP, Rio MC. pS2/TFF1 interacts directly with the VWFC cysteine-rich domains of mucins. Gastroenterol-ogy 2000; 118: 70-80 [PMID: 10611155 DOI: 10.1016/S0016-5085(00)70415-X]
33. Albert TK, Laubinger W, Müller S, Hanisch FG, Kalinski T, Meyer F, Hoffmann W. Human intestinal TFF3 forms disulfide-linked heteromers with the mucus-associated FCGBP protein and is released by hydrogen sulfde. J Pro-teome Res 2010; 9: 3108-3117 [PMID: 20423149 DOI: 10.1021/ pr100020c]
34. Dignass A, Lynch-Devaney K, Kindon H, Thim L, Podolsky DK. Trefoil peptides promote epithelial migration through a transforming growth factor beta-independent pathway. J Clin Invest 1994; 94: 376-383 [PMID: 8040278 DOI: 10.1172/ JCI117332]
35. Tan XD, Liu QP, Hsueh W, Chen YH, Chang H, Gonzalez-Crussi F. Intestinal trefoil factor binds to intestinal epithelial cells and induces nitric oxide production: priming and enhancing effects of mucin. Biochem J 1999; 338 (Pt 3): 745-751 [PMID: 10051448 DOI: 10.1042/0264-6021:3380745]
36. Itoh H, Tomita M, Uchino H, Kobayashi T, Kataoka H, Seki-ya R, Nawa Y. cDNA cloning of rat pS2 peptide and expression of trefoil peptides in acetic acid-induced colitis. Biochem J 1996; 318 (Pt 3): 939-944 [PMID: 8836141]
37. Mashimo H, Wu DC, Podolsky DK, Fishman MC. Impaired defense of intestinal mucosa in mice lacking intestinal trefoil factor. Science 1996; 274: 262-265 [PMID: 8824194 DOI: 10.1126/science.274.5285.262]
38. Beck PL, Wong JF, Li Y, Swaminathan S, Xavier RJ, Dev-aney KL, Podolsky DK. Chemotherapy- and radiotherapy-induced intestinal damage is regulated by intestinal trefoil factor. Gastroenterology 2004; 126: 796-808 [PMID: 14988834 DOI: 10.1053/j.gastro.2003.12.004]
39. Playford RJ, Marchbank T, Chinery R, Evison R, Pignatelli M, Boulton RA, Thim L, Hanby AM. Human spasmolytic polypeptide is a cytoprotective agent that stimulates cell migration. Gastroenterology 1995; 108: 108-116 [PMID: 7806031 DOI: 10.1016/0016-5085(95)90014-4]
40. McKenzie C, Marchbank T, Playford RJ, Otto W, Thim L, Parsons ME. Pancreatic spasmolytic polypeptide protects the gastric mucosa but does not inhibit acid secretion or mo-tility. Am J Physiol 1997; 273: G112-G117 [PMID: 9252516]
41. Poulsen SS, Thulesen J, Christensen L, Nexo E, Thim L. Metabolism of oral trefoil factor 2 (TFF2) and the effect of oral and parenteral TFF2 on gastric and duodenal ulcer healing in the rat. Gut 1999; 45: 516-522 [PMID: 10486358 DOI:10.1136/gut.45.4.516]
42. Cook GA, Thim L, Yeomans ND, Giraud AS. Oral human spasmolytic polypeptide protects against aspirin-induced gastric injury in rats. J Gastroenterol Hepatol 1998; 13: 363-370 [PMID: 9641298]
43. Babyatsky MW, deBeaumont M, Thim L, Podolsky DK. Oral trefoil peptides protect against ethanol- and indometh-acin-induced gastric injury in rats. Gastroenterology 1996; 110: 489-497 [PMID: 8566596 DOI: 10.1053/gast.1996.v110. pm8566596]
44. Soriano-Izquierdo A, Gironella M, Massaguer A, May FE, Salas A, Sans M, Poulsom R, Thim L, Piqué JM, Panés J. Trefoil peptide TFF2 treatment reduces VCAM-1 expression and leukocyte recruitment in experimental intestinal infam-mation. J Leukoc Biol 2004; 75: 214-223 [PMID: 14597729 DOI: 10.1189/jlb.0803396]
45. Kjellev S, Thim L, Pyke C, Poulsen SS. Cellular localization, binding sites, and pharmacologic effects of TFF3 in experimental colitis in mice. Dig Dis Sci 2007; 52: 1050-1059 [PMID: 17342398 DOI: 10.1007/s10620-006-9256-4]
46. FitzGerald AJ, Pu M, Marchbank T, Westley BR, May FE, Boyle J, Yadollahi-Farsani M, Ghosh S, Playford RJ. Syner-gistic effects of systemic trefoil factor family 1 (TFF1) pep-tide and epidermal growth factor in a rat model of colitis. Peptides 2004; 25: 793-801 [PMID: 15177874 DOI: 10.1016/ j.peptides.2003.12.022]
47. Poulsen SS, Kissow H, Hare K, Hartmann B, Thim L. Luminal and parenteral TFF2 and TFF3 dimer and monomer in two models of experimental colitis in the rat. Regul Pept 2005; 126: 163-171 [PMID: 15664663 DOI: 10.1016/ j.regpep.2004.09.007]
48. Marchbank T, Westley BR, May FE, Calnan DP, Playford RJ. Dimerization of human pS2 (TFF1) plays a key role in its protective/healing effects. J Pathol 1998; 185: 153-158 [PMID: 9713341]
49. Tran CP, Cook GA, Yeomans ND, Thim L, Giraud AS. Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces infammation in a rat model of colitis. Gut 1999; 44: 636-642 [PMID: 10205199 DOI: 10.1136/ gut.44.5.636]
50. Giraud AS, Pereira PM, Thim L, Parker LM, Judd LM. TFF-2 inhibits iNOS/NO in monocytes, and nitrated protein in healing colon after colitis. Peptides 2004; 25: 803-809 [PMID: 15177875 DOI: 10.1016/j.peptides.2004.01.019]
51. Chinery R, Playford RJ. Combined intestinal trefoil factor and epidermal growth factor is prophylactic against indo-methacin-induced gastric damage in the rat. Clin Sci (Lond) 1995; 88: 401-403 [PMID: 7789040]
52. Poulsen SS, Thulesen J, Nexø E, Thim L. Distribution and metabolism of intravenously administered trefoil factor 2/porcine spasmolytic polypeptide in the rat. Gut 1998; 43: 240-247 [PMID: 10189851 DOI: 10.1136/gut.43.2.240]
53. Kjellev S, Nexø E, Thim L, Poulsen SS. Systemically administered trefoil factors are secreted into the gastric lumen and increase the viscosity of gastric contents. Br J Pharmacol 2006; 149: 92-99 [PMID: 16880764 DOI: 10.1038/sj.bjp.0706840]
54. Vandenbroucke K, Hans W, Van Huysse J, Neirynck S, Demetter P, Remaut E, Rottiers P, Steidler L. Active delivery of trefoil factors by genetically modified Lactococcus lactis prevents and heals acute colitis in mice. Gastroenter-ology 2004; 127: 502-513 [PMID: 15300583 DOI: 10.1053/ j.gastro.2004.05.020]
55. Sun Y, Zhu Y, Wang L, Mao X, Peng X, Peng Y. Recom-binant adenovirus-mediated intestinal trefoil factor gene therapy for burn-induced intestinal mucosal injury. PLoS One 2013; 8: e62429 [PMID: 23638081 DOI: 10.1371/journal. pone.0062429]
56. Loncar MB, Al-azzeh ED, Sommer PS, Marinovic M, Schmehl K, Kruschewski M, Blin N, Stohwasser R, Gött P, Kayademir T. Tumour necrosis factor alpha and nuclear factor kappaB inhibit transcription of human TFF3 encoding a gastrointestinal healing peptide. Gut 2003; 52: 1297-1303 [PMID: 12912861]
57. Teng X, Xu LF, Zhou P, Sun HW, Sun M. Effects of trefoil peptide 3 on expression of TNF-alpha, TLR4, and NF-kappaB in trinitrobenzene sulphonic acid induced colitis mice. In-fammation 2009; 32: 120-129 [PMID: 19238529 DOI: 10.1007/ s10753-009-9110-x]
58. Podolsky DK, Gerken G, Eyking A, Cario E. Colitis-associated variant of TLR2 causes impaired mucosal repair because of TFF3 defciency. Gastroenterology 2009; 137: 209-220 [PMID: 19303021 DOI: 10.1053/j.gastro.2009.03.007]
59. Wright NA, Poulsom R, Stamp GW, Hall PA, Jeffery RE, Longcroft JM, Rio MC, Tomasetto C, Chambon P. Epidermal growth factor (EGF/URO) induces expression of regulatory peptides in damaged human gastrointestinal tissues. J Pathol 1990; 162: 279-284 [PMID: 2290113]
60. Nunez AM, Berry M, Imler JL, Chambon P. The 5' flanking region of the pS2 gene contains a complex enhancer region responsive to oestrogens, epidermal growth factor, a tumour promoter (TPA), the c-Ha-ras oncoprotein and the c-jun protein. EMBO J 1989; 8: 823-829 [PMID: 2498085]
61. Liu D, el-Hariry I, Karayiannakis AJ, Wilding J, Chinery R, Kmiot W, McCrea PD, Gullick WJ, Pignatelli M. Phosphory-lation of beta-catenin and epidermal growth factor receptor by intestinal trefoil factor. Lab Invest 1997; 77: 557-563 [PMID: 9426392]
62. Borniquel S, Jädert C, Lundberg JO. Dietary conjugated lin-oleic acid activates PPARγ and the intestinal trefoil factor in SW480 cells and mice with dextran sulfate sodium-induced colitis. J Nutr 2012; 142: 2135-2140 [PMID: 23077197]
63. Hoffmann W, Jagla W, Wiede A. Molecular medicine of TFF-peptides: from gut to brain. Histol Histopathol 2001; 16: 319-334 [PMID: 11193208]
64. Matsuoka Y, Pascall JC, Brown KD. Quantitative analysis reveals differential expression of mucin (MUC2) and intestinal trefoil factor mRNAs along the longitudinal axis of rat intestine. Biochim Biophys Acta 1999; 1489: 336-344 [PMID: 10673034 DOI: 10.1016/S0167-4781(99)00186-4]
65. Wright NA, Poulsom R, Stamp G, Van Norden S, Sarraf C, Elia G, Ahnen D, Jeffery R, Longcroft J, Pike C. Trefoil peptide gene expression in gastrointestinal epithelial cells in infammatory bowel disease. Scand J Gastroenterol Suppl 1992; 193: 76-82 [PMID: 1290063 DOI: 10.3109/003655292090 96010]
66. Shaoul R, Okada Y, Cutz E, Marcon MA. Colonic expression of MUC2, MUC5AC, and TFF1 in infammatory bowel disease in children. J Pediatr Gastroenterol Nutr 2004; 38: 488-493 [PMID: 15097436 DOI: 10.1097/00005176-200405000-00006]
67. Rio MC, Chenard MP, Wolf C, Marcellin L, Tomasetto C, Lathe R, Bellocq JP, Chambon P. Induction of pS2 and hSP genes as markers of mucosal ulceration of the digestive tract. Gastroenterology 1991; 100: 375-379 [PMID: 1985035]
68. Longman RJ, Poulsom R, Corfeld AP, Warren BF, Wright NA, Thomas MG. Alterations in the composition of the su-pramucosal defense barrier in relation to disease severity of ulcerative colitis. J Histochem Cytochem 2006; 54: 1335-1348 [PMID: 16924127 DOI: 10.1369/jhc.5A6904.2006]
69. Wright NA, Pike C, Elia G. Induction of a novel epidermal growth factor-secreting cell lineage by mucosal ulceration in human gastrointestinal stem cells. Nature 1990; 343: 82-85 [PMID: 2296294 DOI: 10.1038/343082a0]
70. Madsen J, Sorensen GL, Nielsen O, Tornøe I, Thim L, Fenger C, Mollenhauer J, Holmskov U. A variant form of the human deleted in malignant brain tumor 1 (DMBT1) gene shows increased expression in inflammatory bowel diseases and interacts with dimeric trefoil factor 3 (TFF3). PLoS One 2013; 8: e64441 [PMID: 23691218 DOI: 10.1371/ journal.pone.0064441]
71. Kjellev S, Vestergaard EM, Nexø E, Thygesen P, Eghøj MS, Jeppesen PB, Thim L, Pedersen NB, Poulsen SS. Pharmaco-kinetics of trefoil peptides and their stability in gastrointestinal contents. Peptides 2007; 28: 1197-1206 [PMID: 17466412 DOI: 10.1016/j.peptides.2007.03.016]
72. Samson MH. Quantitative measurements of trefoil factor family peptides: possibilities and pitfalls. Scand J Clin Lab Invest 2013; 73: 193-202 [PMID: 23391285 DOI: 10.3109/0036 5513.2013.765962]
73. Vestergaard EM, Poulsen SS, Grønbaek H, Larsen R, Nielsen AM, Ejskjaer K, Clausen JT, Thim L, Nexø E. Development and evaluation of an ELISA for human trefoil factor 3. Clin Chem 2002; 48: 1689-1695 [PMID: 12324485]
74. Vestergaard EM, Brynskov J, Ejskjaer K, Clausen JT, Thim L, Nexø E, Poulsen SS. Immunoassays of human trefoil factors 1 and 2: measured on serum from patients with infammatory bowel disease. Scand J Clin Lab Invest 2004; 64: 146-156 [PMID: 15115253 DOI: 10.1080/00365510410001176]
75. Grønbaek H, Vestergaard EM, Hey H, Nielsen JN, Nexø E. Serum trefoil factors in patients with infammatory bowel disease. Digestion 2006; 74: 33-39 [PMID: 17068395]
76. Mahmood A, Melley L, Fitzgerald AJ, Ghosh S, Playford RJ. Trial of trefoil factor 3 enemas, in combination with oral 5-aminosalicylic acid, for the treatment of mild-to-moderate left-sided ulcerative colitis. Aliment Pharmacol Ther 2005; 21: 1357-1364 [PMID: 15932366 DOI: 10.1111/ j.1365-2036.2005.02436.x]